tiprankstipranks
Trending News
More News >
Fresenius Medical Care AG & Co. KGaA (DE:FME)
XETRA:FME
Advertisement

Fresenius Medical Care AG & Co. KGaA (FME) AI Stock Analysis

Compare
15 Followers

Top Page

DE:FME

Fresenius Medical Care AG & Co. KGaA

(XETRA:FME)

Select Model
Select Model
Select Model
Outperform 70 (OpenAI - 4o)
Rating:70Outperform
Price Target:
€48.00
▲(9.29% Upside)
Fresenius Medical Care AG & Co. KGaA's overall stock score is driven primarily by its strong financial performance, characterized by consistent revenue growth and robust cash flow management. The technical analysis suggests moderate momentum with some resistance in the longer term. Valuation metrics are fair, providing a balanced view of the stock's potential.
Positive Factors
Revenue Growth
Consistent revenue growth at 13% indicates strong demand for dialysis products and services, supporting long-term business expansion and market leadership.
Cash Flow Management
Strong free cash flow growth of 20.07% highlights effective cash management, ensuring liquidity for investments and operational stability.
Balance Sheet Health
Improved debt-to-equity ratio of 0.75 indicates better leverage management, enhancing financial stability and reducing risk exposure.
Negative Factors
Profitability Margins
Decreasing EBIT and EBITDA margins suggest challenges in maintaining operating efficiency, potentially impacting long-term profitability.
Return on Equity
Low return on equity at 4.38% indicates limited profitability from equity, which may affect investor confidence and capital efficiency.
Net Profit Margin
While improved, a net profit margin of 3.17% remains relatively low, potentially limiting reinvestment capacity and shareholder returns.

Fresenius Medical Care AG & Co. KGaA (FME) vs. iShares MSCI Germany ETF (EWG)

Fresenius Medical Care AG & Co. KGaA Business Overview & Revenue Model

Company DescriptionFresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
How the Company Makes MoneyFresenius Medical Care generates revenue primarily through two key streams: the sale of dialysis products and the provision of dialysis services. The product segment includes the manufacturing and distribution of dialysis machines, dialyzers, and other related consumables, which are sold to hospitals, clinics, and other healthcare providers. The service segment involves the operation of a vast number of dialysis clinics globally, where patients receive treatment on a regular basis. Revenue from services is typically derived from reimbursement payments from government programs, private insurers, and out-of-pocket payments from patients. Additionally, the company benefits from partnerships with healthcare providers and payers, which can enhance its service delivery and expand its market reach. Factors such as an aging population, the increasing prevalence of chronic kidney disease, and advancements in dialysis technology also contribute to its earnings potential.

Fresenius Medical Care AG & Co. KGaA Financial Statement Overview

Summary
Fresenius Medical Care shows stable financial performance with consistent revenue and profit margins, a balanced capital structure, and strong cash generation capabilities. However, growth is relatively flat, and leverage remains moderately high.
Income Statement
75
Positive
Fresenius Medical Care experienced a slight revenue decline of approximately 0.6% from 2023 to 2024, following a similar trend from previous years. Despite this, the company maintained a strong gross profit margin of around 24.6% in 2024, reflecting efficient cost management. However, the net profit margin decreased slightly from 2.6% in 2023 to 2.8% in 2024. The EBIT margin improved slightly, indicating better operational profitability. Overall, the income statement reveals stable but not strong growth, with consistent margins indicating good operational efficiency.
Balance Sheet
70
Positive
The balance sheet shows a debt-to-equity ratio of approximately 0.75 in 2024, indicating a moderate level of leverage. The equity ratio of 43.4% suggests a balanced capital structure, though slightly lower than desirable for long-term stability. The return on equity (ROE) improved to 3.7% in 2024, reflecting better profitability. Overall, the balance sheet indicates adequate financial health with manageable leverage, but there is room for improvement in equity levels and returns.
Cash Flow
80
Positive
In 2024, operating cash flow decreased by 9.2% compared to 2023, yet free cash flow remained strong. The free cash flow to net income ratio was significant, indicating good cash generation relative to profits. However, the decrease in operating cash flow and free cash flow compared to previous years suggests potential challenges in maintaining cash generation levels. Overall, the cash flow statement shows a solid cash position but highlights the need for improved cash flow growth.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue19.52B19.34B19.45B19.40B17.62B17.86B
Gross Profit4.81B4.76B4.93B5.31B5.08B5.54B
EBITDA3.09B3.21B2.93B3.22B3.42B3.83B
Net Income656.43M537.91M499.00M673.40M969.31M1.16B
Balance Sheet
Total Assets31.29B33.57B33.93B35.75B34.37B31.69B
Cash, Cash Equivalents and Short-Term Investments2.19B1.45B1.54B1.44B1.62B1.24B
Total Debt11.02B10.98B12.05B13.21B13.32B12.38B
Total Liabilities16.96B17.80B19.10B20.30B20.39B19.36B
Stockholders Equity13.27B14.58B13.62B15.45B13.98B12.33B
Cash Flow
Free Cash Flow2.05B1.69B1.94B1.44B1.64B2.15B
Operating Cash Flow2.75B2.39B2.63B2.17B2.49B4.23B
Investing Cash Flow-578.46M-84.94M-544.23M-734.73M-1.20B-1.33B
Financing Cash Flow-1.51B-2.57B-1.86B-1.62B-1.02B-2.66B

Fresenius Medical Care AG & Co. KGaA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price43.92
Price Trends
50DMA
43.17
Positive
100DMA
45.97
Negative
200DMA
44.86
Negative
Market Momentum
MACD
0.14
Negative
RSI
56.01
Neutral
STOCH
66.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:FME, the sentiment is Positive. The current price of 43.92 is above the 20-day moving average (MA) of 42.83, above the 50-day MA of 43.17, and below the 200-day MA of 44.86, indicating a neutral trend. The MACD of 0.14 indicates Negative momentum. The RSI at 56.01 is Neutral, neither overbought nor oversold. The STOCH value of 66.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:FME.

Fresenius Medical Care AG & Co. KGaA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
€50.88B23.5512.29%2.06%5.85%16.20%
70
Outperform
€12.76B19.634.83%3.30%0.53%23.79%
70
Outperform
€46.65B16.2910.13%2.01%1.67%9.02%
60
Neutral
€3.81B24.058.75%1.42%5.21%-39.36%
58
Neutral
€12.18B128.035.03%0.37%3.80%33.31%
50
Neutral
€27.23B-8.11-11.25%0.39%-1.99%-169.98%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:FME
Fresenius Medical Care AG & Co. KGaA
44.66
7.34
19.68%
DE:BAYN
Bayer
28.23
-2.07
-6.83%
DE:AFX
Carl Zeiss Meditec
42.16
-23.53
-35.82%
DE:MRK
Merck KGaA
109.45
-44.11
-28.72%
DE:SRT3
Sartorius
193.05
-53.02
-21.55%
DE:SHL
Siemens Healthineers AG
46.02
-6.27
-12.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 27, 2025